The proportion with incident delayed filling at 1 year was similar among eyes treated with ranibizumab ( 10 [ 2.4 % ] of 413 ) or bevacizumab ( 13 [ 3.3 % ] of 385 ; P = .53 ) and among eyes treated monthly ( 12 [ 3.1 % ] of 388 ) or as needed ( 11 [ 2.7 % ] of 410 ; P = .83 ) .